398 related articles for article (PubMed ID: 16051889)
21. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.
Lin CY; Gurlo T; Haataja L; Hsueh WA; Butler PC
J Clin Endocrinol Metab; 2005 Dec; 90(12):6678-86. PubMed ID: 16204373
[TBL] [Abstract][Full Text] [Related]
22. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway.
Chang PC; Chen TH; Chang CJ; Hou CC; Chan P; Lee HM
Kidney Int; 2004 May; 65(5):1664-75. PubMed ID: 15086905
[TBL] [Abstract][Full Text] [Related]
23. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
Liu D; Zeng BX; Zhang SH; Yao SL
Inflamm Res; 2005 Nov; 54(11):464-70. PubMed ID: 16307220
[TBL] [Abstract][Full Text] [Related]
24. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways.
Wei-guo Z; Hui Y; Shan L; Yun Z; Wen-cheng N; Fu-lin Y; Fang-yan F; Jun-hua G; Jian-hua Z
Immunol Cell Biol; 2010; 88(3):305-12. PubMed ID: 19997078
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
Benkirane K; Viel EC; Amiri F; Schiffrin EL
Hypertension; 2006 Jan; 47(1):102-8. PubMed ID: 16344371
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models.
Gu J; Liu X; Wang QX; Guo M; Liu F; Song ZP; Zhang DD
J Mol Cell Cardiol; 2013 Dec; 65():1-8. PubMed ID: 24100253
[TBL] [Abstract][Full Text] [Related]
27. 15-deoxy-Delta12,14 prostaglandin GJ2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms in cardiac cells.
Hovsepian E; Penas F; Goren NB
Shock; 2010 Jul; 34(1):60-7. PubMed ID: 19997048
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium.
Scirpo R; Fiorotto R; Villani A; Amenduni M; Spirli C; Strazzabosco M
Hepatology; 2015 Nov; 62(5):1551-62. PubMed ID: 26199136
[TBL] [Abstract][Full Text] [Related]
29. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
30. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.
He Z; Zhang X; Chen C; Wen Z; Hoopes SL; Zeldin DC; Wang DW
Cardiovasc Res; 2015 Mar; 105(3):304-17. PubMed ID: 25618409
[TBL] [Abstract][Full Text] [Related]
31. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Ye P; Fang H; Zhou X; He YL; Liu YX
Chin Med Sci J; 2004 Dec; 19(4):243-7. PubMed ID: 15669179
[TBL] [Abstract][Full Text] [Related]
32. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
Hou X; Zhang Y; Shen YH; Liu T; Song S; Cui L; Bu P
Eur J Pharmacol; 2013 Sep; 715(1-3):196-203. PubMed ID: 23791613
[TBL] [Abstract][Full Text] [Related]
33. [The effect of relgulation of PPAR-α on cardiac hypertrophy and the relationship between the effect of PPAR-α with PI3K/Akt/mTOR pathway].
Wu Y; Wang BX; Guo YY; Wang YQ
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2015 May; 31(3):284-8. PubMed ID: 26387199
[TBL] [Abstract][Full Text] [Related]
34. [Effects of rosiglitazone on peroxisome proliferator activated receptor-γ pathway in patients with chronic obstructive pulmonary disease].
Zeng XL; Liu XJ; Bao HR; Zhang Y; Tan EL; Liao JM
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Oct; 34(10):743-8. PubMed ID: 22321707
[TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells.
Wang WM; Chen H; Zhong F; Lu Y; Han L; Chen N
Am J Nephrol; 2011; 34(2):152-62. PubMed ID: 21734368
[TBL] [Abstract][Full Text] [Related]
37. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.
Ding G; Fu M; Qin Q; Lewis W; Kim HW; Fukai T; Bacanamwo M; Chen YE; Schneider MD; Mangelsdorf DJ; Evans RM; Yang Q
Cardiovasc Res; 2007 Nov; 76(2):269-79. PubMed ID: 17678635
[TBL] [Abstract][Full Text] [Related]
38. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
39. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Liu DS; Liu WJ; Chen L; Ou XM; Wang T; Feng YL; Zhang SF; Xu D; Chen YJ; Wen FQ
Toxicology; 2009 Jun; 260(1-3):112-9. PubMed ID: 19464576
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
